4.7 out of 5 (43 Reviews)



Post Assessment Questions


Start Date

1 Sep 2023

Last Review Date

12 Nov 2023

Expiration Date

31 Aug 2026

Estimated Time To Finish

60 Minutes

Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Zolmitriptan is a pharmaceutical medication utilized for managing and treating acute migraines. Zolmitriptan belongs to the triptan class of drugs that targets migraine symptoms and provides relief to patients. The underlying cause of migraines can be attributed to localized cranial vasodilatation coupled with the discharge of neuropeptides, including calcitonin gene-related peptide, vasoactive intestinal peptide (VIP), and substance P, within the trigeminal system. Zolmitriptan is a selective 5-hydroxytryptamine (5-HT) 1B/1D receptor agonist with moderate affinity for the 5-HT 1A receptor subtypes. Zolmitriptan's interaction with 5-HT 1B/1D receptors induces vasoconstriction of intracranial blood vessels, concurrently inhibiting the release of proinflammatory neuropeptides from trigeminal perivascular nerve endings. This educational activity provides insights into the applications, mechanism of action, and contraindications of zolmitriptan as a valuable agent in treating acute migraines. This activity also highlights the adverse events, toxicity concerns, and other pivotal considerations, including off-label applications, dosage guidelines, pharmacokinetics, monitoring procedures, and relevant interactions, which are crucial for healthcare practitioners when managing migraine issues and associated ailments in patients.

Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Screen patients for contraindications, potential drug interactions, and underlying health conditions that could influence zolmitriptan's safe and effective use.

  • Implement zolmitriptan into treatment plans, considering factors such as dosage, formulation, timing of treatment, and administration routes based on individual patient needs.

  • Apply evidence-based guidelines to optimize the use of zolmitriptan for migraine management, including proper patient education on medication administration, potential adverse effects, and early treatment initiation.

  • Communicate effectively with patients about zolmitriptan therapy's benefits, risks, and potential adverse effects, ensuring they are informed and engaged in shared decision-making with their healthcare providers.


StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


Physicians and Physician Associates: StatPearls, LLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians and PAs should only claim credit commensurate with the extent of their participation in the activity.

American Board of Anesthesiology: This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in AnesthesiologyTM (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

American Board of Internal Medicine: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Royal College of Physicians and Surgeons of Canada: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.


This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.




Alana H. on 8/26/2021

Harry A. on 10/17/2021

Sarah A. on 11/16/2021

1. Text states: "Zolmitriptan is the generic formulation of two branded products." How about naming those products? 2. Text stats: "The maximum recommended daily dose is 10mg for adults and pediatric patients ages 12 to 17." This sentence does not flow well.

john e. on 2/14/2022

Janice on 3/15/2022

Dr Haresh D. on 3/28/2022

cyvada s. on 5/4/2022

Christine D. on 5/13/2022

Paul H. on 5/14/2022

Shelia C. on 5/15/2022

Megan G. on 5/19/2022

Alexandra G. on 6/13/2022

Rohit A. on 7/6/2022

Brittany T. on 8/1/2022

victoria s. on 8/23/2022

Alex N. on 8/30/2022

Emily A. on 9/19/2022

Mark O. on 10/24/2022

Kecia T. on 12/26/2022

long h. on 12/27/2022

Laurie C. on 12/28/2022

Natalie p. on 1/3/2023

Connie D. on 1/3/2023

Lisa B. on 1/29/2023

Nancy H. on 1/30/2023

Dr Jagveer S. on 3/26/2023

John C. on 4/2/2023

Sushma B. on 4/17/2023

Daniela E. on 4/26/2023

Quinn C. on 5/13/2023

Christy S. on 6/30/2023

Apurva S. on 7/8/2023

VLADIMIR E. on 7/18/2023

Whittney H. on 8/7/2023

Haleigh K. on 9/24/2023

Theresa M. on 10/5/2023

roxanna g. on 10/7/2023

Jordan L. on 10/22/2023

Denise W. on 11/5/2023

Sheetal G. on 12/28/2023

Kathleen . on 12/29/2023


Laurence R. on 12/31/2023

Brittany C. on 2/6/2024

Unlimited Physician CME

Stay up to date on the latest medical knowledge with 6689 CME activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7943 hours of CME.

Learn About Lifetime CME

Single Activity

Take this single activity

$49 1 activity

6 Month Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$399 per half year per user

1 Year Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$599 per 1 year per user